Scorpius Holdings, Inc. Announces Closing of Public Offering
Scorpius Holdings, Inc. (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has closed its underwritten public offering of 14,375,000 shares of common stock and/or pre-funded warrants. The offering, priced at $1.00 per share, raised gross proceeds of $14,375,000. This includes the full exercise of the underwriter's over-allotment option. ThinkEquity acted as the sole book-running manager for the offering.
The company plans to use the net proceeds for working capital and general corporate purposes. Scorpius Holdings specializes in rapidly advancing biologic and cell therapy programs, offering analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, TX.
Scorpius Holdings, Inc. (NYSE American: SCPX), un'organizzazione di sviluppo e produzione a contratto (CDMO), ha chiuso la sua offerta pubblica ventennale sottoscritta di 14.375.000 azioni ordinarie e/o warrant pre-finanziati. L'offerta, valutata a 1,00 $ per azione, ha raccolto proventi lordi di 14.375.000 $. Questo include l'esercizio completo dell'opzione di sovrallocazione dell'assicuratore. ThinkEquity ha agito come unico gestore del libro per l'offerta.
L'azienda prevede di utilizzare i proventi netti per il capitale operativo e scopi aziendali generali. Scorpius Holdings è specializzata nell'avanzamento rapido di programmi biologici e di terapia cellulare, offrendo test analitici, sviluppo dei processi e servizi di produzione a compagnie farmaceutiche e biotecnologiche nelle sue strutture a San Antonio, TX.
Scorpius Holdings, Inc. (NYSE American: SCPX), una organización de desarrollo y manufactura por contrato (CDMO), ha cerrado su oferta pública suscrita de 14,375,000 acciones ordinarias y/o garantías prefinanciadas. La oferta, valorada en $1.00 por acción, recaudó ingresos brutos de $14,375,000. Esto incluye el ejercicio completo de la opción de sobreasignación del suscriptor. ThinkEquity actuó como el único gerente de libro para la oferta.
La empresa planea utilizar los ingresos netos para capital de trabajo y propósitos corporativos generales. Scorpius Holdings se especializa en avanzar rápidamente programas biológicos y de terapia celular, ofreciendo servicios de pruebas analíticas, desarrollo de procesos y manufactura a empresas farmacéuticas y biotecnológicas en sus instalaciones en San Antonio, TX.
스코르피우스 홀딩스, Inc. (NYSE American: SCPX)는 계약 개발 및 제조 조직(CDMO)으로서 공모를 마감했습니다. 보통주 및/또는 사전 자금이 지원된 워런트 14,375,000주를 포함한 이번 공모는 주당 $1.00로 가격이 책정되었습니다. 총 14,375,000$의 gross 수익이 발생했습니다. 여기에는 주관사의 초과 배정 옵션의 전액 행사가 포함되어 있습니다. ThinkEquity는 이 공모의 단독 북런닝 매니저로 활동했습니다.
회사는 순수익을 운영 자본 및 일반 사업 목적으로 사용할 계획입니다. 스코르피우스 홀딩스는 생물학 및 세포 치료 프로그램을 빠르게 발전시키는 데 전문화되어 있으며, 샌안토니오, TX에 있는 시설에서 제약 및 생명공학 회사에 분석 테스트, 공정 개발 및 제조 서비스를 제공합니다.
Scorpius Holdings, Inc. (NYSE American: SCPX), une organisation de développement et de fabrication sous contrat (CDMO), a achevé son offre publique souscrite de 14 375 000 actions ordinaires et/ou de bons de souscription préfinancés. L'offre, évaluée à 1,00 $ par action, a permis de lever un produit brut de 14 375 000 $. Cela inclut l'exercice complet de l'option de surallocation de l'initiateur de l'offre. ThinkEquity a agi en tant que seul gestionnaire de livre pour l'offre.
L'entreprise prévoit d'utiliser les produits nets pour le fonds de roulement et des fins d'entreprise générales. Scorpius Holdings se spécialise dans l'avancement rapide de programmes biologiques et de thérapie cellulaire, offrant des tests analytiques, le développement de processus et des services de fabrication aux entreprises pharmaceutiques et biopharmaceutiques dans ses installations à San Antonio, TX.
Scorpius Holdings, Inc. (NYSE American: SCPX), eine Vertragsentwicklungs- und Produktionsorganisation (CDMO), hat ihr unterzeichnetes öffentliches Angebot abgeschlossen von 14.375.000 Aktien des Stammkapitals und/oder vorfinanzierten Optionsscheinen. Das Angebot, das mit 1,00 $ pro Aktie bepreist wurde, brachte brutto Einnahmen von 14.375.000 $ ein. Dies beinhaltet die volle Ausübung der Überbelegungsoption des Underwriters. ThinkEquity fungierte als alleiniger Buchführer für das Angebot.
Das Unternehmen plant, die netto Einnahmen für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Scorpius Holdings ist spezialisiert auf die schnelle Entwicklung biologischer und Zelltherapieprogramme und bietet analytische Tests, Prozessentwicklung und Fertigungsdienste für Pharma- und Biotechunternehmen in seinen Einrichtungen in San Antonio, TX.
- Successful closing of public offering, raising $14,375,000 in gross proceeds
- Full exercise of underwriter's over-allotment option, indicating strong demand
- Funds to be used for working capital and general corporate purposes, potentially strengthening the company's financial position
- Potential dilution of existing shareholders due to the issuance of 14,375,000 new shares
- Offering price of $1.00 per share may be lower than the current market price, potentially impacting stock value
Insights
Scorpius Holdings' public offering of
The full exercise of the underwriter's over-allotment option indicates strong demand for the offering. Yet, the use of pre-funded warrants alongside common stock could imply a complex financial structure, potentially diluting existing shareholders. Investors should closely monitor how effectively Scorpius utilizes this capital to drive growth in its CDMO business, particularly in the competitive biologics and cell therapy sectors.
As a CDMO focusing on large molecules, biologics and cell therapies, Scorpius is positioned in a high-growth sector of the pharmaceutical industry. The
However, the relatively small size of this offering for a CDMO suggests Scorpius may be a smaller player in the field. Investors should assess how this capital infusion will enhance Scorpius' competitive edge against larger, more established CDMOs. The company's ability to attract and retain pharmaceutical clients, especially for advanced therapies, will be critical for long-term success in this technically demanding and rapidly evolving industry.
DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 14,375,000 shares of common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), including full exercise of the underwriter’s over-allotment option. Each share of common stock (or Pre-Funded Warrant) was offered at a public offering price of
The Company intends to use the net proceeds of the offering to fund working capital and for general corporate purposes.
ThinkEquity acted as sole book-running manager for the offering.
A registration statement on Form S-1 (File No. 333-280887) relating to the securities being offered was filed with the Securities and Exchange Commission (“SEC”) and became effective on August 6, 2024. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated large molecule contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and include statements regarding the intended use of proceeds. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to complete the proposed offering, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly report on Form 10-Q and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this press release on account of new information, future events, or otherwise, except as required by law.
For Investor Relations Inquiries:
David Waldman
+1 (919)-289-4017
investorrelations@nighthawkbio.com
FAQ
How much did Scorpius Holdings (SCPX) raise in its recent public offering?
What was the offering price for Scorpius Holdings' (SCPX) public offering?
How many shares did Scorpius Holdings (SCPX) offer in its public offering?
What will Scorpius Holdings (SCPX) use the proceeds from the public offering for?
